Cargando…

Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center

BACKGROUND: Immune tolerance induction (ITI) can reduce inhibitors against factor VIII concentrates by 70-80%. In this study, we elucidated the characteristics of inhibitors and attempted to determine the proper indications and timing for ITI. METHODS: Subjects included hemophilia A patients registe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoo, Ki Young, Joo, Sang Chun, Choi, Yong Mook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828527/ https://www.ncbi.nlm.nih.gov/pubmed/27104190 http://dx.doi.org/10.5045/br.2016.51.1.37

Ejemplares similares

The prevalence of anti-factor VIII and anti-factor IX antibodies among patients with hemophilia in Rabat, Morocco: a single center experience
por: Bouyadmar, Meryem, et al.
Publicado: (2022)

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A
por: Oh, Jisu, et al.
Publicado: (2013)

Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study
por: Kim, Soon Ki, et al.
Publicado: (2017)

Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
por: Chen, Zhen-Ping, et al.
Publicado: (2018)

Recombinant single‐chain factor VIII in severe hemophilia: Long‐term safety and efficacy in previously treated patients in the AFFINITY extension study
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
por: Hermans, Cedric, et al.
Publicado: (2023)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
por: Doshi, Bhavya S., et al.
Publicado: (2012)

Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
por: Chen, Chun-Yu, et al.
Publicado: (2020)

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022)

P1626: A SINGLE-CENTER EXPERIENCE IN INCREASING FACTOR VIII LEVELS TO ACHIEVE ZERO BLEEDING IN PATIENTS WITH SEVERE HEMOPHILIA A.
por: López, Rubén Clavero, et al.
Publicado: (2023)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Immune tolerance induction in patients with severe hemophilia A with inhibitors
por: Ryu, Ji Eun, et al.
Publicado: (2015)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
por: Lieuw, Kenneth
Publicado: (2017)

Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine
por: Mahmoud Abu Arra, Caesar, et al.
Publicado: (2020)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study
por: Vautier, Mathieu, et al.
Publicado: (2016)

The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017)

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A
por: Delignat, Sandrine, et al.
Publicado: (2019)

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
por: Brown, Harrison C, et al.
Publicado: (2014)

P1670: LONG TERM SAFETY AND EFFICACY OF RECOMBINANT HUMAN COAGULATION FACTOR VIII (SCT800) IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A
por: Xue, F., et al.
Publicado: (2022)

Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors
por: Miao, Carol H.
Publicado: (2016)

Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
por: Han, Jeong Pil, et al.
Publicado: (2021)

B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
por: Chen, Alex C., et al.
Publicado: (2020)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
por: Moon, Byung Suk, et al.
Publicado: (2013)

Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor VIII in Mice with Hemophilia A
por: Roth, Stefanie D., et al.
Publicado: (2012)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
por: Di Minno, Giovanni, et al.
Publicado: (2019)

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice
por: Lai, Jesse D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hfll7ptbjfi2uin0ohcnffqhab